Stehlin Foundation For Cancer Research  

Read Stehlin's past and current newsletters

Most recent newsletters include an update on DSRCT research

Stehlin needs tumor samples - contact Doug Coil for information on how you can help.  Information on preserving the tumor samples and the Informed Consent Form are available to view and print out.  Instructions :  Link 

Informed Consent : Link

For more info, contact Doug Coil at the Stehlin Foundation :     (713) 756-5750

    The Stehlin Foundation in Houston, Texas has agreed to devote some of their resources to study DSRCT.  Stehlin is a private research facility that was established in 1969.  Their patients receive personalized treatment from their physicians and research scientists based upon their specific needs.

    Stehlin made an offer to all DSRCT patients to be included in their nude mouse program free of charge!    Here is a link to some various treatments performed at Stehlin  :  LINK

    Here is a brief description on what a nude mouse is:  LINK

    On 12/17/04, my wife and I were given a tour of the Stehlin laboratory by the foundation's executive director, Bobby Anderson.  After the tour, we had a meeting with the lab's director and four of their researchers.  I would never have imagined that I could be given access to this many cancer researchers all at one time!  We all set around a table and discussed what can be done NOW for DSRCT patients. 


Stehlin Foundation Executive Director Bobby Anderson and myself with some nude mice.   (12/17/04)

Nude Mouse Program

    Stehlin will not charge anyone with DSRCT to participate in this program!  Stehlin takes a piece of tumor and grows it on the backs of these special mice.  Many drug combinations are tried on these mice and the results are charted so that the patient can see what drugs work or won't work on their specific tumor.  

    Below is a very basic example of what a Stehlin tumor chart looks like.  DSRCT tumors will be tested against both standard and experimental drugs.


    Stehlin said that they will make themselves available to speak with DSRCT patients or their doctors in the future so they can share the info that we will be compiling in our DSRCT database.  Stehlin will be glad to give tours of their laboratory any time that a patient is in Houston.



Stehlin News & Announcements

 5/05/06:  Doug Coil from Stehlin sent this update:


     Several DSRCT patients have sent us tumor biopsies to be grown in tissue culture and transplanted into our nude (athymic) mouse model. Four tumor specimens are now growing in nude mice; two are growing in tissue culture. When compared to other solid cancers (colon, lung, melanoma, etc.) DSRCT tumors are extremely difficult to grow in either tissue culture or the nude mouse. We are convinced, however, that with hard work and persistence we can establish these DSRCT cancers for long term study.


To enhance our DSRCT studies, we recently purchased a $20,000 fluorescent microscope. This instrument will allow us to take the next step, which is to splice a green fluorescent protein (GFP) into the DSRCT cell. The DSRCT tumor, with the incorporated GFP, will be implanted into the nude mouse model. Once the tumor is growing and established, we will treat the tumor with conventional and experimental anticancer drugs. The treatment success or failure of these agents can be determined by simply observing the fluorescence of the DSRCT tumor. With this research plan, we should be able to identify the most effective chemotherapeutic agents for DSRCT patients.

I have also including a PDF of our lab update, which includes a section on DSRCT.  

  2/16/05:  Dr. Constantine Markides from Stehlin sent this update:

     We have received the two tumor kits back from Canada and California. We have injected samples from both into some nude mice and are waiting to see if they will grow. Historically we have a 20-25% take rate.  That is better for some tumor types than for others.  Since we don't have any comparison for DSRCT (the one Ewings sarcoma we implanted has yet to show signs of growth) we don't really know what kind of take rate we'll have.

12/21/04:  Doug Coil from Stehlin wanted to me update our DSRCT group on their progress.

          You can tell those DSCRT patients that you are in communication with that the ball is rolling. I know that when you or a family member has cancer (I don't know of a family that has not been touched by cancer!), that it can get frustrating unless you know that 'something' is being done! We are doing something, and we will continue to press this issue of approval of the Informed Consent. In the interim, we will start working with some of our established sarcoma tumors that we have in the lab.


     I want to inform you that the vast amount of research that we have performed over the past 30+ years developing treatments for solid tumors, including the drug Camptothecin and its’ derivatives, may be of benefit to our new research of DSRCT. We fully expect to ‘jump start’ this new research based upon our broad background of  knowledge. We certainly do not feel that we are starting from ‘scratch’ on this project and hopefully we will see some tangible results in 2005.







         If you are already scheduled for a biopsy or surgery, please consider sending the Stehlin Foundation some of your tumor!  Your fellow DSRCT patients will deeply appreciate it!

  Patrick Scranton

(713) 952-9597  Home,   (713) 675-5374  Work,   (800) 775-5374  Work



Stehlin is a non-profit cancer research center, and as such, they perform this type of research via donations from corporations and the general public.  Donations may be made via their website:





     I am not a medical or health professional.  Information in this site has been gathered from numerous sources and is for research purposes only.  I do not guarantee the accuracy of any information in this site.    Desmoplastic Small Round Cell Tumor